An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A

Key Inclusion Criteria:

- Ability of the participant's legally authorized representative (e.g. their parent or
legal guardian) to understand the purpose and risks of the study and provide signed
and dated informed consent and authorization to use confidential health information in
accordance with national and local subject privacy regulations.

- Weight >=3.5 kg at the time of screening.

- Severe hemophilia A defined as <1 IU/dL (<1%) endogenous FVIII documented in the
medical record or as tested during the Screening Period

Key Exclusion Criteria:

- Any exposure to blood components, factor VIII replacement products, including
commercially available rFVIIIFc at any time prior to or during screening.

- Other coagulation disorder(s) in addition to hemophilia A.

- Any concurrent clinically significant major disease that, in the opinion of the
Investigator, would make the participant unsuitable for enrollment.

- Current systemic treatment with chemotherapy and/or other immunosuppressant drugs.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.